MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway - PubMed (original) (raw)

. 2015 Jan 22;34(4):413-23.

doi: 10.1038/onc.2013.574. Epub 2014 Jan 27.

J Li 1, M Yan 1, L Liu 1, H Lin 1, F Zhao 1, L Sun 1, Y Zhang 1, Y Cui 1, F Zhang 1, J Li 1, X He 1, M Yao 1

Affiliations

• PMID: 24469061
• DOI: 10.1038/onc.2013.574

MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway

T Yu et al. Oncogene. 2015.

Abstract

The metastatic cascade is a complex and multistep process with many potential barriers. Recent evidence has shown that microRNAs (miRNAs) are involved in carcinogenesis and tumor progression in non-small-cell lung cancer (NSCLC). In this study, by comparing the miRNA expression profiles of SPC-A-1sci (high metastatic) and SPC-A-1 (weakly metastatic) cells, we demonstrated that the downregulation and function of miR-193a-3p and miR-193a-5p in NSCLC metastasis and the expression of these miRNAs was suppressed in NSCLC compared with corresponding non-tumorous tissues. Decreased miR-193a-3p/5p expression was significantly associated with tumor node metastasis (TNM) and lymph node metastasis. Furthermore, functional assays showed that the overexpression of miR-193a-3p/5p inhibited NSCLC cell migration, invasion and epithelial-mesenchymal transition (EMT) in vitro and lung metastasis formation in vivo. In addition, we discovered that ERBB4 and S6K2 were the direct targets of miR-193a-3p and that PIK3R3 and mTOR were the direct targets of miR-193a-5p in NSCLC. We also observed that miR-193a-3p/5p could inactivate the AKT/mTOR signaling pathway. Thus, miR-193a-3p/5p functions as a tumor suppressor and has an important role in NSCLC metastasis through ERBB signaling pathway.

PubMed Disclaimer

Similar articles

• Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers.
  Chen J, Gao S, Wang C, Wang Z, Zhang H, Huang K, Zhou B, Li H, Yu Z, Wu J, Chen C. Chen J, et al. J Exp Clin Cancer Res. 2016 Nov 7;35(1):173. doi: 10.1186/s13046-016-0450-8. J Exp Clin Cancer Res. 2016. PMID: 27821145 Free PMC article.
• Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells.
  Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X, Wang E. Jiang L, et al. BMC Cancer. 2010 Jun 22;10:318. doi: 10.1186/1471-2407-10-318. BMC Cancer. 2010. PMID: 20569443 Free PMC article.
• miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.
  Liang H, Liu M, Yan X, Zhou Y, Wang W, Wang X, Fu Z, Wang N, Zhang S, Wang Y, Zen K, Zhang CY, Hou D, Li J, Chen X. Liang H, et al. J Biol Chem. 2015 Jan 9;290(2):926-40. doi: 10.1074/jbc.M114.621409. Epub 2014 Nov 12. J Biol Chem. 2015. PMID: 25391651 Free PMC article.
• The outstanding role of miR-132-3p in carcinogenesis of solid tumors.
  Rafat M, Moraghebi M, Afsa M, Malekzadeh K. Rafat M, et al. Hum Cell. 2021 Jul;34(4):1051-1065. doi: 10.1007/s13577-021-00544-w. Epub 2021 May 17. Hum Cell. 2021. PMID: 33997944 Review.
• A review on the role of LINC00152 in different disorders.
  Ghafouri-Fard S, Askari A, Hussen BM, Rasul MF, Taheri M, Kiani A. Ghafouri-Fard S, et al. Pathol Res Pract. 2023 Jan;241:154274. doi: 10.1016/j.prp.2022.154274. Epub 2022 Dec 13. Pathol Res Pract. 2023. PMID: 36563561 Review.

Cited by

• Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer.
  Zhu K, Ding H, Wang W, Liao Z, Fu Z, Hong Y, Zhou Y, Zhang CY, Chen X. Zhu K, et al. Oncotarget. 2016 May 10;7(19):28075-85. doi: 10.18632/oncotarget.8576. Oncotarget. 2016. PMID: 27057632 Free PMC article.
• MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma.
  Lin CH, Tsai CH, Yeh CT, Liang JL, Hung WC, Lin FC, Chang WL, Li HY, Yao YC, Hsu TI, Lee YC, Wang YC, Sheu BS, Lai WW, Calkins MJ, Hsiao M, Lu PJ. Lin CH, et al. Oncotarget. 2016 Jun 28;7(26):39680-39693. doi: 10.18632/oncotarget.9444. Oncotarget. 2016. PMID: 27203740 Free PMC article.
• The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis.
  Wang W, Shen XB, Jia W, Huang DB, Wang Y, Pan YY. Wang W, et al. Ther Adv Med Oncol. 2019 May 23;11:1758835919850665. doi: 10.1177/1758835919850665. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31205511 Free PMC article.
• High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids.
  Rapa I, Votta A, Gatti G, Izzo S, Buono NL, Giorgio E, Vatrano S, Napoli F, Scarpa A, Scagliotti G, Papotti M, Volante M. Rapa I, et al. Oncotarget. 2018 Jun 8;9(44):27535-27546. doi: 10.18632/oncotarget.25541. eCollection 2018 Jun 8. Oncotarget. 2018. PMID: 29938004 Free PMC article.
• Expression of metastasis-associated lung adenocarcinoma transcript 1 long non-coding RNA in vitro and in patients with non-small cell lung cancer.
  Lin L, Li H, Zhu Y, He S, Ge H. Lin L, et al. Oncol Lett. 2018 Jun;15(6):9443-9449. doi: 10.3892/ol.2018.8531. Epub 2018 Apr 18. Oncol Lett. 2018. PMID: 29805668 Free PMC article.

References

1. 1. Sci Transl Med. 2013 Feb 6;5(171):171ra18 - PubMed
2. 1. PLoS One. 2012;7(8):e43452 - PubMed
3. 1. J Pathol. 2011 Jan;223(2):102-15 - PubMed
4. 1. Clin Cancer Res. 2011 Dec 15;17(24):7574-83 - PubMed
5. 1. J Exp Med. 2013 Apr 8;210(4):789-803 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal